Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 12, 2023

Efficacy of Oral SERDs in Patients With ER+/HER2− Metastatic Breast Cancer Stratified by ESR1 Wild-Type and Mutant Subgroups

Annals of Oncology


Additional Info

Annals of Oncology
Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups
Ann. Oncol 2023 Oct 21;[EPub Ahead of Print], NZH Wong, DWT Yap, RJM Ong, JJ Zhao, YH Chan, JCS Tey, R Sundar, JSJ Lim, SS Dawood

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading